EDEN PRAIRIE, MINN., - June 8, 2026 (NEWMEDIAWIRE) - NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company dedicated to transforming the surgical diagnosis and treatment of neurological disorders, today announced that the Company will participate in the Planet MicroCap Las Vegas 2026 Conference June 17-18, 2026.
Dave Rosa, President & Chief Executive Officer, will attend the Planet MicroCap Conference in Las Vegas, NV where he is scheduled to host one-on-one meetings with institutional investors. Mr. Rosa is also scheduled to deliver a Company presentation on Wednesday, June 17, 2026, at 12:00 p.m. Pacific Time/3:00 p.m. Eastern Time in TRACK 6 - Raphael 3 and will provide commercialization updates and anticipated milestones for the OneRF® platform for treatment of the brain, pain, and advanced drug delivery.
Mr. Rosa also took part in a CEO interview with Planet MicroCap host Robert Kraft ahead of the conference and can be viewed here.
Planet MicroCap Las Vegas 2026 Conference
Attendee: Dave Rosa, President & Chief Executive Officer
Format: In-person 1x1 Meetings, Company Presentation, and CEO Interview
Presentation: Wednesday, June 17, 2026, at 12:00 p.m. Pacific Time/3:00 p.m. Eastern Time in TRACK 6 - Raphael 3
Webcast Link: Here
Conference Website: Here
CEO Interview: Here
For more information on the Planet MicroCap Las Vegas 2026 Conference, or to schedule a meeting with management, please contact your conference representative or you may also email your request to NMTC@mzgroup.us or call Chris Tyson at (949) 491-8235.
About NeuroOne
NeuroOne Medical Technologies Corporation is a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders. NeuroOne markets a minimally invasive and high-definition/high-precision electrode technology platform with four FDA-cleared product families: Evo® Cortical Electrodes, Evo® sEEG Electrodes, OneRF® Ablation System (for brain), and OneRF® Trigeminal Nerve Ablation System. These solutions offer the potential to reduce the number of hospitalizations and surgical procedures, lower costs, and improve patient outcomes by offering diagnostic and therapeutic functions. The Company is engaged in research and development for drug delivery, basivertebral nerve ablation and spinal cord stimulation programs. For more information, visit nmtc1.com.
Caution: Federal law restricts this device to sale by or on the order of a physician.
IR Contact
MZ Group – MZ North America
NMTC@mzgroup.us
View the original release on www.newmediawire.com
